1. |
Vu M, Yu J, Awolude OA, et al. Cervical cancer worldwide. Curr Probl Cancer, 2018, 42(5): 457-465.
|
2. |
Li K, Li Q, Song L, et al. The distribution and prevalence of human papillomavirus in women in mainland China. Cancer, 2019, 125(7): 1030-1037.
|
3. |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
|
4. |
Lowy DR, Solomon D, Hildesheim A, et al. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer, 2008, 113(7 Suppl): 1980-1993.
|
5. |
Zeng Z, Yang H, Li Z, et al. Prevalence and genotype distribution of HPV infection in China: analysis of 51, 345 HPV genotyping results from China's largest CAP certified laboratory. J Cancer, 2016, 7(9): 1037-1043.
|
6. |
Li K, Yin R, Wang D, et al. Human papillomavirus subtypes distribution among 2309 cervical cancer patients in West China. Oncotarget, 2017, 8(17): 28502-28509.
|
7. |
丁贤彬, 吕晓燕, 毛德强, 等. 2010-2017 年重庆市宫颈癌疾病负担变化趋势分析. 中国肿瘤, 2019, 28(9): 657-662.
|
8. |
董惠玲, 杨瑞贞, 赵飞燕, 等. 2012 年山东省主要恶性肿瘤疾病负担评价. 中国肿瘤, 2016, 25(1): 20-24.
|
9. |
GBD. Global health data exchange. Available at: http://ghdx.healthdata.org/gbd-results-tool.
|
10. |
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet, 2020, 396(10258): 1204-1222.
|
11. |
GBD 2013 DALYs and HALE Collaborators, Murray CJ, Barber RM, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet, 2015, 386(10009): 2145-2191.
|
12. |
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, et al. The Global Burden of Cancer 2013. JAMA Oncol, 2015, 1(4): 505-527.
|
13. |
Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859): 2163-2196.
|
14. |
Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet, 2016, 387(10015): 251-272.
|
15. |
GBD 2013 Risk Factors Collaborators, Forouzanfar MH, Alexander L, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet, 2015, 386(10010): 2287-2323.
|
16. |
齐金蕾, 王黎君, 周脉耕, 等. 1990-2013 年中国男性前列腺癌疾病负担分析. 中华流行病学杂志, 2016, 37(6): 778-782.
|
17. |
Shrestha AD, Neupane D, Vedsted P, et al. Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review. Asian Pac J Cancer Prev, 2018, 19(2): 319-324.
|
18. |
郑诗丹, 王晓平. 宫颈癌发病率与患者生活因素的相关性研究. 齐齐哈尔医学院学报, 2016, 37(5): 572-573.
|
19. |
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1999, 189(1): 12-19.
|
20. |
Canfell K, Kim JJ, Brisson M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet, 2020, 395(10224): 591-603.
|
21. |
Zhao F, Qiao Y. Cervical cancer prevention in China: a key to cancer control. Lancet, 2019, 393(10175): 969-970.
|
22. |
Hancock G, Hellner K, Dorrell L. Therapeutic HPV vaccines. Best Pract Res Clin Obstet Gynaecol, 2018, 47: 59-72.
|
23. |
Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol, 2013, 10(7): 400-410.
|
24. |
Laprise JF, Chesson HW, Markowitz LE, et al. Effectiveness and cost-effectiveness of human papillomavirus vaccination through age 45 years in the United States. Ann Intern Med, 2020, 172(1): 22-29.
|
25. |
Sundström K, Elfström KM. Advances in cervical cancer prevention: Efficacy, effectiveness, elimination? PLoS Med, 2020, 17(1): e1003035.
|
26. |
García-Perdomo HA, Osorio JC, Fernandez A, et al. The effectiveness of vaccination to prevent the papillomavirus infection: a systematic review and meta-analysis. Epidemiol Infect, 2019, 147: e156.
|
27. |
WHO. Accelerating the elimination of cervical cancer as a global public health problem. Available at: https://apps.who.int/gb/ebwha/pdf_files/EB144/B144(2)-en.pdf.
|
28. |
Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med, 2018, 7(10): 5217-5236.
|
29. |
谢珊艳, 任鹏. 宫颈癌发病年轻化的趋势分析与相应对策. 中医药管理杂志, 2018, 26(5): 10-12.
|
30. |
任春丽. 近 20 年长春地区宫颈癌发病趋势和临床病例分析. 吉林: 吉林大学, 2006.
|
31. |
Pimple SA, Mishra GA. Global strategies for cervical cancer prevention and screening. Minerva Ginecol, 2019, 71(4): 313-320.
|
32. |
Ogilvie G, Nakisige C, Huh WK, et al. Optimizing secondary prevention of cervical cancer: Recent advances and future challenges. Int J Gynaecol Obstet, 2017, 138(Suppl 1): 15-19.
|